June 24, 2019 by
Pillar Biosciences is happy to announce that the Columbia Solid Tumor Panel, a custom Pillar® NGS panel designed by Dr. Helen Fernandes and colleagues at the Columbia University Medical Center (CUMC) Laboratory of Personalized Genomic Medicine, has received conditional approval for clinical use by the New York State Department of Health.
The panel leverages Pillar’s proprietary SLIMamp® enrichment chemistry and single-tube amplification for an easy workflow that will allow CUMC to rapidly deliver genomic insights for clinical diagnostics. Dr. Fernandes and her team have presented validation data at both domestic and international conferences that demonstrates the panel’s robust analytical performance, sensitive variant detection with low DNA input, and a rapid turnaround time from sample to answer.
Ultimately, CUMC is leveraging Pillar technology to improve patient outcomes with more efficient and reliable clinical decision making. “We evaluated other solid tumor panels and found that the single-tube amplification used in this panel worked best for us in terms of workflow, assay performance, and cost,” said Dr. Helen Fernandes, Co-Director of Genomic Oncology at the Laboratory of Personalized Genomic Medicine at CUMC.
Learn more and see the validation data of the Columbia Solid Tumor Panel at the link below: